The Aeson total artificial heart provides right- and left-sided heart replacement for biventricular failure with notable improvements from prior generations. These include enhanced hemocompatibility and autoregulation enabling increased output in response to higher filling pressures. We report the first clinical implantation in the United States as part of an early feasibility study. The patient was successfully bridged to transplant after 5 months of support on the device and has made a full recovery.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11708379 | PMC |
http://dx.doi.org/10.1016/j.atssr.2022.09.007 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!